GlassScriptPhysician profile
Ellen C Gendler
NPI 1891997409
$35,174.55
in general payments reported to CMS, 2019-2025
19 companies · $654 in 2025
The $654 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $3,950 · 2021: $4,697 · 2022: $2,935 · 2023: $344 · 2024: $606 · 2025: $654.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,316 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $238 · Education: $50.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,316.39 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $237.50 |
| Education | $50.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $31,487.61 | 2019-2022 | |
| Merz North America, INC. | $1,256.68 | 2019-2020 | |
| Abbvie INC. | $979.64 | 2022-2025 | |
| Revance Therapeutics, INC. | $404.03 | 2024-2025 | Daxxify |
| Novartis Pharmaceuticals Corporation | $160.44 | 2021-2025 | |
| Janssen Biotech, INC. | $132.74 | 2022-2025 | Tremfya |
| Almirall LLC | $101.73 | 2021-2022 | |
| Lilly USA, LLC | $94.48 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Incyte Corporation | $87.13 | 2021-2023 | Opzelura |
| Galderma Laboratories, L.P. | $79.75 | 2019-2024 | Aklief |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $70.71 | 2019-2021 | |
| Endo Pharmaceuticals INC. | $67.57 | 2019 | |
| Sun Pharmaceutical Industries INC. | $59.60 | 2019-2023 | Absorica Ld, Winlevi |
| Vyne Pharmaceuticals INC. | $52.94 | 2020-2021 | |
| Ucb, INC. | $47.88 | 2022-2023 | Bimzelx |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $26.55 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $23.89 | 2024 | Sotyktu |
| Aclaris Therapeutics, INC. | $21.88 | 2019 | |
| Leo Pharma INC. | $19.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellen Gendler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.